CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop new antibacterial hybrid biomedical polymers to combat drug-resistant infections. It focuses on creating innovative materials with intrinsic antibacterial properties and training researchers to advance therapeutic strategies in healthcare.
There is a general consensus that biomedical polymers of natural and synthetic origin should and will play a very important role in the development of new therapeutic strategies to treat diseases.
Due to resistance of bacteria to drugs, infection has become one of the toughest problems in the medical world as there are hardly any effective antibiotics left in the fight against many pathogens.
This project aims to develop new therapies through a new combination of technology (a) development of ne…
LUCIDEON LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, London
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Torino
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Erlangen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
ASHLAND SPECIALTIES IRELAND LIMITED
Ireland, MULLINGAR, WESTMEATH
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
